Deep Dives, AI, Drug Development, Drug Discovery.
Up until recently Alban de La Sablière was Sanofi’s chief dealmaker, reporting directly to CEO Paul Hudson. In October he left to become Chief Business Officer at Owkin, a French AI scale-up focused on drug development and delivery. For Dr. Thomas Clozel, Owkin’s CEO, the move is evidence of a